• Copyright 2016
  • Privacy Policy
  • Terms of Use
  • Sign In
  • Home
  • About Us
    • About Us Overview
    • Vision and Mission
    • Key Milestones
    • Leadership
      • Leadership Overview
      • Ronald Zenk
      • Colin G. Chinn, M.D.
      • Michael Kaytor, Ph.D.
      • Scott Thatcher
      • Matthew L. Nathan, M.D.
      • Tim Morris
      • Barbara R. Holcomb, RN, BSN, MSN
      • John Dykstra
      • Jake R. Nunn
      • Thomas F. Jasper
      • Karen L. Smith, M.D.
      • Robert Miller, M.D.
      • Douglas W. Bryce
      • Isabel Jackson, Ph.D.
      • Michael Landauer, Ph.D.
      • Ronald J Manning, Ph.D.
    • Federal Agency Support
    • Intellectual Property
  • Our Technology
    • Our Technology Overview
    • Radiation Modulators
    • Mechanism of Action
    • Safety and Toxicology
    • Pharmacokinetics
    • Relevant Publications
  • Our Focus
    • Our Focus Overview
    • Pipeline
    • Oncology
      • Oncology Overview
      • Non-Small Cell Lung Cancer
      • Head and Neck Cancers
      • Prostate Cancer
    • Inflammatory Lung Diseases
    • Medical Countermeasures
    • Expanded Access Policy
  • News
  • Contact Us

  • Contact Us
  • News
  • Our Focus
  • Our Technology
  • About Us
  • Home

  • Contact Us
  • News
  • Our Focus
  • Our Technology
  • About Us
  • Home

Pharmacokinetics

BIO 300 utilizes a patented nanoparticle oral suspension, which significantly enhances bioavailability and creates near linear absorption characteristics.

  • Radiation Modulators
  • Mechanism of Action
  • Safety and Toxicology
  • Pharmacokinetics
  • Relevant Publications

About Us

  • Key Milestones
  • Leadership
  • Collaboration Partners
  • Intellectual Property

Our Technology

  • Radiation Modulators
  • Mechanism of Action
  • Safety and Toxicology
  • Pharmacokinetics
  • Relevant Publications

Our Focus

  • Pipeline
  • Oncology
  • Medical Countermeasures

News

 

Contact Us

  • Copyright 2016
  • |
  • Privacy Policy
  • |
  • Terms of Use
  • |
  • Sign In